Document 1067 DOCN M9471067 TI Increased survival and development of lymphoma in murine immunodeficiency disease (MAIDS): effects of lithium and magnesium in vivo (Meeting abstract). DT 9409 AU Gallicchio VS; Cibull ML; Hughes NK; Tse KF; Univ. of Kentucky and Veterans Administration Medical Centers,; Lexington, KY 40536 SO FASEB J; 7(4):A692 1993. Unique Identifier : AIDSLINE ICDB/94696889 AB Murine immunodeficiency disease (MAIDS) induced with LP-BM5 strain of MuLV is a disease that shows many similarities to human HIV-infection. Lithium (Li) influences many aspects of immunohematopoietic cellular proliferation and differentiation and is an antagonist to magnesium (Mg) dependent reactions. We describe here results of in vivo studies investigating the effects of Li and Mg (1 mmol placed in the drinking water) treatment in MAIDS-infected mice. Viral control, Li and Mg treated C57BL/6 mice were monitored for survival and MAIDS pathology. Virus-treated mice were grouped to receive Li po as follows: (1) 48 hr before virus; (2) at the same time as virus and (3) 5-wk postvirus. Mg was given 5-wk postvirus. After 22 wk of observation, percent survival was as follows: virus controls, 20%; Mg, 5 wk postvirus, 40%; Li, 5 wk postvirus, 80%; Li, at the time of virus, 85%; and Li, 48 hr prior to virus, 100% survival. Lymphoma, measured by splenomegaly (gms) was significantly reduced: normal age-matched controls 0.1 +/- 0.01; virus controls, 0.83 +/- 0.2, Mg, 5 wk postvirus, 1.47 +/- 0.12; Li, 5 wk postvirus, 0.47 +/- 0.02; and Li, at the time of virus, 0.28 +/- 0.1 (p value less than 0.01). These data suggest cations such as Mg and Li may play an important role in MAIDS pathogenesis and also indicates Li may be an efficacious agent in altering the pathogenesis and lymphoma characteristic of this retroviral disease in mice. DE Animal Cell Division/*DRUG EFFECTS Lithium/PHARMACOLOGY/*THERAPEUTIC USE Lymphoma/COMPLICATIONS/*DRUG THERAPY Magnesium/PHARMACOLOGY/*THERAPEUTIC USE Mice Mice, Inbred C57BL Murine Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG THERAPY/PATHOLOGY MEETING ABSTRACT SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).